101 related articles for article (PubMed ID: 30807642)
21. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
22. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
23. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
Tate S; Hirai Y; Takeshima N; Hasumi K
Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
[TBL] [Abstract][Full Text] [Related]
24. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
Cheraghchi-Bashi A; Parker CA; Curry E; Salazar JF; Gungor H; Saleem A; Cunnea P; Rama N; Salinas C; Mills GB; Morris SR; Kumar R; Gabra H; Stronach EA
Oncotarget; 2015 Dec; 6(39):41736-49. PubMed ID: 26497682
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.
May T; Stewart JM; Bernardini MQ; Ferguson SE; Laframboise S; Jiang H; Rosen B
Int J Gynaecol Obstet; 2018 Feb; 140(2):247-252. PubMed ID: 29095487
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
28. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
Bowman A; Gabra H; Langdon SP; Lessells A; Stewart M; Young A; Smyth JF
Clin Cancer Res; 2002 Jul; 8(7):2233-9. PubMed ID: 12114425
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of CA125 in patients with ovarian cancer and secondary debulking surgery.
Meier W; Stieber P; Hasholzner U; Gropp M; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2945-7. PubMed ID: 9329571
[TBL] [Abstract][Full Text] [Related]
30. The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer.
He Y; Zhu Q; Chen M; Huang Q; Wang W; Li Q; Huang Y; Di W
Oncotarget; 2016 Oct; 7(43):70803-70821. PubMed ID: 27683123
[TBL] [Abstract][Full Text] [Related]
31. Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.
Pelissier A; Bonneau C; Chéreau E; DE LA Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
Anticancer Res; 2016 Apr; 36(4):1865-71. PubMed ID: 27069172
[TBL] [Abstract][Full Text] [Related]
32. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
[TBL] [Abstract][Full Text] [Related]
33. Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.
Timmermans M; Zwakman N; Sonke GS; Van de Vijver KK; Duk MJ; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():364-369. PubMed ID: 31400565
[TBL] [Abstract][Full Text] [Related]
34. Prediction effects of serum CA125 decrease ratio during different cycles in relapsed ovarian cancer.
Wang J; Liu Y; Li J; Lu X
J Obstet Gynaecol Res; 2019 May; 45(5):1006-1011. PubMed ID: 30687999
[TBL] [Abstract][Full Text] [Related]
35. Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development.
Wilbaux M; Hénin E; Oza A; Colomban O; Pujade-Lauraine E; Freyer G; Tod M; You B
Gynecol Oncol; 2014 Jun; 133(3):460-6. PubMed ID: 24726614
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
Riedinger JM
Bull Cancer; 2007 Mar; 94(3):287-95. PubMed ID: 17371771
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker.
Zhang X; Li H; Yu X; Li S; Lei Z; Li C; Zhang Q; Han Q; Li Y; Zhang K; Wang Y; Liu C; Mao Y; Wang X; Irwin DM; Guo H; Niu G; Tan H
Cell Physiol Biochem; 2018; 48(5):1983-1994. PubMed ID: 30092594
[TBL] [Abstract][Full Text] [Related]
38. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
39. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer.
Walker G; MacLeod K; Williams AR; Cameron DA; Smyth JF; Langdon SP
Clin Cancer Res; 2007 Mar; 13(5):1438-44. PubMed ID: 17332286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
